Cellectar Biosciences, Inc.

CLRB

$2.36

+0.43%

2026-09-04 09:44:57 EDT+$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's ...

Insider Transactions of CLRB

Acquisitions (A)

Since Jul 7, 2026

Disposals (D)

Since Jul 7, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 8, 2026	Loren Stefan	other: Consultant	Stock option (right to buy)	A	15,000	$2.69
Jul 8, 2026	Loren Stefan	other: Consultant	Stock option (right to buy)	A	15,000	$2.68
Jul 7, 2026	Kolean Chad J	officer: CFO	Stock option (right to buy)	A	92,000	$3.14
Jul 7, 2026	DRISCOLL FREDERICK W	director	Stock option (right to buy)	A	25,000	$2.70
Jul 7, 2026	Chanan-Khan Asher	director	Stock option (right to buy)	A	25,000	$2.70

Insider Trading Snapshot

Acquisitions (A)

Disposals (D)

Total Shares Bought

627,500

Total Shares Sold

Monthly Insider Activity

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Transactions by Title - Shares

X-axis: shares, sorted by total shares desc

Transactions by Title - Counts

X-axis: counts, sorted by A+D counts desc

Key People: Buy/Sell Activity and Price

CARUSO JAMES V

director, officer: President & CEO • 1 txns

Loren Stefan

other: Consultant • 2 txns

Kolean Chad J

officer: CFO • 1 txns

DRISCOLL FREDERICK W

director • 1 txns

Transactions Table

Date	Executive	Title	Security	Side	Shares	Price	Value
Jul 8, 2026	Loren Stefan	other: Consultant	Stock option (right to buy)	A	15,000	$2.69	$40,350.00
Jul 8, 2026	Loren Stefan	other: Consultant	Stock option (right to buy)	A	15,000	$2.68	$40,200.00
Jul 7, 2026	Kolean Chad J	officer: CFO	Stock option (right to buy)	A	92,000	$3.14	$288,880.00
Jul 7, 2026	DRISCOLL FREDERICK W	director	Stock option (right to buy)	A	25,000	$2.70	$67,500.00
Jul 7, 2026	Chanan-Khan Asher	director	Stock option (right to buy)	A	25,000	$2.70	$67,500.00
Jul 7, 2026	CARUSO JAMES V	director, officer: President & CEO	Stock option (right to buy)	A	250,000	$3.14	$785,000.00
Jul 7, 2026	Gu Andrew	director	Stock option (right to buy)	A	25,000	$2.70	$67,500.00
Jul 7, 2026	Longcor Jarrod	officer: Chief Operating Officer	Stock option (right to buy)	A	118,000	$3.14	$370,520.00
Jul 7, 2026	Swirsky Douglas J	director	Stock option (right to buy)	A	37,500	$2.70	$101,250.00
Jul 7, 2026	NEIS JOHN	director	Stock option (right to buy)	A	25,000	$2.70	$67,500.00

Supply Chain of CLRB

RELATIONS

Upstream

SpectronRxLantheus Holdings (via Evergreen Theragnostics acquisition)NASDAQ:LNTHNorthStar Medical RadioisotopesITM Isotope Technologies Munich SENusanoIonetix CorporationUnconfirmed

Downstream

MiBA (Meaningful Insights-BioTech Analytics) / American Oncology NetworkOTCPK:AONCEvestia ClinicalMayo Clinic

Proxies

Actinium Pharmaceuticals, Inc.NYSEAM:ATNMPerspective Therapeutics, Inc.NYSE:CATX Lantheus Holdings, Inc.NASDAQ:LNTH

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer